Key facts
- It has raised $2.3M; the latest was Seed Round ($2.0M) in Jan 2025.
- Notable investors include Capital BioVentures, FACIT, GKCC, McMaster University.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Esphera SynBio
- ·The full record, as it builds
Funding rounds
No funding rounds for Esphera SynBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Esphera SynBio
Operator of a biotechnology company intended to develop cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through its proprietary transgene technology, enabling pharmaceutical companies to focus on enhancing mRNA vaccine efficacy for infectious diseases.
- Sector
- Healthcare
- HQ
- Ottawa, Canada
- Founded
- 2022
- Employees
- 10
- Website
- espherasynbio.ca/
- Ownership
- Privately Held (backing)
Esphera SynBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Esphera SynBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Esphera SynBio in its N-PORT filings yet. We sweep new filings monthly.